UNSPSC 51183705: Rosiglitazone

This classification denotes a differentiation inducer and anti-diabetic agent with the molecular formula C18H19N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 05V02F2KDG, chemically known as 2,4-thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)- but more generally known as rosiglitazone, which bears US NIH Compound Identifier 77999. European Medicines Agency schedules Rosiglitazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10388MIG.

UNSPSC 51183705 Rosiglitazone, a Commodity code, encompasses rosiglitazone maleate tablets and related pharmaceutical formulations supplied through state and local government cooperative purchasing frameworks. State and local procurement under this code routes through multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions and their authorized healthcare and social-service facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body active in recent solicitation activity, procuring generic pharmaceuticals on behalf of member states and local entities.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products (S1070000015802) is the recent representative opportunity under this code. The solicitation, due March 26, 2026, establishes multiple contracts for pharmaceutical products including rosiglitazone to be distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencara, Cardinal Health, and Morris & Dickson Co., LLC). Vendors must supply products with specific National Drug Codes and maintain contractual relationships with at least two of the three authorized wholesalers, certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and meet a $5 million commercial general liability insurance requirement. Contract term runs two years for new responders with optional extensions, or through June 30, 2028 for incumbent vendors. Award is based on price competitiveness (75 percent weight), fixed pricing for contract term (10 percent), EDI capability (5 percent), administrative fee format compliance (5 percent), and agreement to a 3 percent administrative fee (5 percent). No specific set-aside designations or disadvantaged-enterprise restrictions apply per the available RFP documentation.